GSK pulls plans to market anemia drug in EU and other markets, citing ‘reduced opportunity’

It ap­pears GSK’s Jes­du­vroq will not launch in new mar­kets for now, with the phar­ma gi­ant with­draw­ing its bid to mar­ket the ane­mia drug in Eu­rope as well as ceas­ing fil­ing in oth­er ter­ri­to­ries.

GSK dis­closed in its sec­ond quar­ter earn­ings an­nounce­ment that it’s de­cid­ed not to com­mer­cial­ize Jes­du­vroq (dapro­du­s­tat) in Eu­rope for the treat­ment of ane­mia among chron­ic kid­ney dis­ease pa­tients. While the EMA’s CHMP did rec­om­mend its use in pa­tients on chron­ic main­te­nance dial­y­sis, it ex­clud­ed those who are not de­pen­dent on dial­y­sis — a “sig­nif­i­cant re­duc­tion in the size of the op­por­tu­ni­ty,” ac­cord­ing to the com­pa­ny.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN